MA48625A - Composés et méthodes de traitement de la douleur viscérale - Google Patents

Composés et méthodes de traitement de la douleur viscérale

Info

Publication number
MA48625A
MA48625A MA048625A MA48625A MA48625A MA 48625 A MA48625 A MA 48625A MA 048625 A MA048625 A MA 048625A MA 48625 A MA48625 A MA 48625A MA 48625 A MA48625 A MA 48625A
Authority
MA
Morocco
Prior art keywords
methods
visceral pain
pain treatment
treatment compounds
compounds
Prior art date
Application number
MA048625A
Other languages
English (en)
Inventor
Cheryl Geraldine Lassen
Marcelo Fabian Piccirillo
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA48625A publication Critical patent/MA48625A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA048625A 2017-05-08 2018-05-08 Composés et méthodes de traitement de la douleur viscérale MA48625A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762503280P 2017-05-08 2017-05-08

Publications (1)

Publication Number Publication Date
MA48625A true MA48625A (fr) 2020-03-18

Family

ID=62245468

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048625A MA48625A (fr) 2017-05-08 2018-05-08 Composés et méthodes de traitement de la douleur viscérale

Country Status (13)

Country Link
US (2) US20200078358A1 (fr)
EP (1) EP3621619B1 (fr)
JP (1) JP7247106B2 (fr)
KR (1) KR20200005614A (fr)
CN (1) CN110709085A (fr)
AU (1) AU2018266145A1 (fr)
BR (1) BR112019023214A2 (fr)
CA (1) CA3062824A1 (fr)
EA (1) EA201992638A1 (fr)
ES (1) ES2956059T3 (fr)
MA (1) MA48625A (fr)
MX (2) MX2019013311A (fr)
WO (1) WO2018208848A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202330496A (zh) * 2021-10-05 2023-08-01 美商艾尼納製藥公司 用於製備大麻素受體調節劑之結晶形式及方法
WO2023150648A2 (fr) * 2022-02-02 2023-08-10 Makscientific, Llc Compositions pharmaceutiques, leur préparation et leurs méthodes d'utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103539785B (zh) 2009-08-28 2015-09-23 艾尼纳制药公司 大麻素受体调节剂
US9597340B2 (en) * 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
ES2932441T3 (es) * 2011-02-25 2023-01-19 Arena Pharm Inc Formas cristalinas y procesos para la preparación de azaciclos condensados (moduladores de los receptores cannabinoides)
MX346644B (es) * 2011-02-25 2017-03-14 Arena Pharm Inc Moduladores de receptores canabinoides.
CA3019842A1 (fr) * 2016-04-10 2017-10-19 Arena Pharmaceuticals, Inc. Methodes de traitement par des agonistes de recepteur cb2
WO2018208847A1 (fr) * 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compositions et méthodes pour le traitement de la douleur résultant de la maladie inflammatoire chronique de l'intestin
EP3684353A4 (fr) * 2017-09-22 2021-06-23 Inmed Pharmaceuticals Inc. Formulations topiques de cannabinoïdes et leur utilisation dans le traitement de la douleur
EP4301366A2 (fr) * 2021-03-02 2024-01-10 Arena Pharmaceuticals, Inc. Méthodes de traitement avec des agonistes sélectifs du récepteur cb2
TW202330496A (zh) * 2021-10-05 2023-08-01 美商艾尼納製藥公司 用於製備大麻素受體調節劑之結晶形式及方法

Also Published As

Publication number Publication date
EA201992638A1 (ru) 2020-03-18
US20200078358A1 (en) 2020-03-12
US20230033510A1 (en) 2023-02-02
MX2019013311A (es) 2020-08-03
EP3621619A1 (fr) 2020-03-18
MX2022008265A (es) 2022-08-04
CA3062824A1 (fr) 2018-11-15
AU2018266145A1 (en) 2019-11-28
BR112019023214A2 (pt) 2020-05-26
JP7247106B2 (ja) 2023-03-28
CN110709085A (zh) 2020-01-17
ES2956059T3 (es) 2023-12-12
KR20200005614A (ko) 2020-01-15
WO2018208848A1 (fr) 2018-11-15
EP3621619C0 (fr) 2023-06-28
JP2020518649A (ja) 2020-06-25
EP3621619B1 (fr) 2023-06-28

Similar Documents

Publication Publication Date Title
MA46102A (fr) Composés de tétracycline et méthodes de traitement
MA49631A (fr) Méthodes de traitement de la fibrose kystique
MA54105A (fr) Méthodes de traitement de la fibrose kystique
MA43374A (fr) Méthodes de traitement de tumeurs malignes
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
IT201700081018A1 (it) Trattamento di segnali elettrofisiologici
MA53329A (fr) Méthodes de traitement de l'épilepsie
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
MA53882A (fr) Méthodes de traitement de la sclérose en plaques
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
MA46353A (fr) Méthodes de traitement de l'infertilité féminine
MA54412A (fr) Traitement d'excès de graisse hépatique et/ou viscérale
HK1249865B (zh) 疼痛的治療
FR3039368B1 (fr) Procede de traitement cosmetique
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
MA53553A (fr) Traitement post-chirurgical de la douleur
MA42936A (fr) Procédé de traitement de blessures cardiaques
MA40687A (fr) Méthodes et compositions de traitement de malformation vasculaire
TWI800561B (zh) 毛髮處理方法
MA48625A (fr) Composés et méthodes de traitement de la douleur viscérale
MA48743A (fr) Composés et méthodes de traitement d'infections bactériennes
MA41782A (fr) Traitement de patients atteints de diabète de type 2
MA52738A (fr) Méthodes de traitement de l'arthrite psoriasique
MA53602A (fr) Méthodes de traitement du psoriasis